Lower doses of zoledronic acid may be more effective at reducing fracture risk from osteoporosis
Osteoporosis is a common bone disease that affects millions of Americans, many of whom buy Actonel to relieve their symptoms.
Osteoporosis is a common bone disease that affects millions of Americans, many of whom buy Actonel to relieve their symptoms. Some patients may also benefit from taking zoledronic acid. According to a recent study presented at the 93rd Annual Meeting of the Endocrine Society, taking lower doses of this drug than currently recommended for the prevention of bone fractures could be more effective, and may also increase bone density.
Lead investigator Andrew Grey and his colleagues from the University of Auckland in New Zealand found that as little as one-fifth of the recommended dose can be sufficient to decrease the likelihood of experiencing a fracture resulting from osteoporosis.
Currently, the manufactuers of zoledronic acid advise most patients to have an intravenous infusion of 5 milligrams (mg) each year.
However, the researchers found that taking as little as 1 mg resulted in improved bone density and decreased resorption.
"These results show clearly beneficial effects on bone density and metabolism from lower doses of zoledronate, administered annually," Grey said. "Clinical trials should be undertaken to determine the ability of low doses of zoledronate to prevent fractures."
|
